Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of the current study is to evaluate the potential of the selected PET tracers to detect sarcoidotic lesions in lungs. The tracers are already in clinical use for the detection of certain inflammatory processes or malignant tumors, and their targets present similarities with molecular mechanisms of sarcoidosis.
The diagnosis of sarcoidosis is difficult since there is no specific noninvasive method available to diagnose sarcoidosis. FDG-PET imaging is in use, however, FDG is not a specific tracer for sarcoidosis and other inflammatory diseases may interfere with the imaging findings. The aim of the current protocol is to evaluate the potential of other inflammatory PET-tracers in the detection of sarcoidotic lesions.
The patients with active sarcoidotic lesions in lungs will be recruited. First, the patient undergoes PET-FDG scan and then the patient undergoes the PET scan either with C11-methionine or 68Ga-DOTANOC. The results with the latter tracers will be compared to the imaging results with FDG.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| C11-methionine | Experimental | To compare FDG and C11-methionine in the detection of sarcoidotic lesions. |
|
| 68Ga-Dotanoc | Experimental | To compare FDG and 68Ga-DOTANOC in the detection of sarcoidotic lesions. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Methionine | Drug | Subject undergoes imaging studies with FDG and with methionine. |
|
| Measure | Description | Time Frame |
|---|---|---|
| The detection of sarcoidotic lesion with C11-methionine or 68Ga-DOTANOC. | Qualitative assessment of tracer uptake in sarcoidotic lesions. | baseline |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Riikka Lautamaki, MD, PhD | Contact | +3582 3130000 | riikka.lautamaki@tyks.fi |
| Name | Affiliation | Role |
|---|---|---|
| Juhani Knuuti, MD, PhD | Turku PET Centre, Turku University Hospital, Turku, Finland | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Turku University Hospital | Recruiting | Turku | Southwest Finland | 20520 | Finland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017565 | Sarcoidosis, Pulmonary |
| ID | Term |
|---|---|
| D017563 | Lung Diseases, Interstitial |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D012507 | Sarcoidosis |
Not provided
Not provided
| ID | Term |
|---|---|
| D008715 | Methionine |
| C504894 | 68Ga-DOTANOC |
| ID | Term |
|---|---|
| D000603 | Amino Acids, Sulfur |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D000601 | Amino Acids, Essential |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| DOTANOC | Drug | Subject undergoes imaging studies with FDG and with DOTANOC. |
|
|
| D008232 |
| Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006968 | Hypersensitivity, Delayed |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D000596 |
| Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
| D021542 | Amino Acids, Neutral |